Issue #94
Morning Roost: OpenAI aids Ukraine, Meta's new glasses, and a faster RSA attack
Thursday, September 24, 2026
Today's digest covers OpenAI's extended cyber support for Ukraine and a milestone for OpenAI Academy, along with two Meta announcements on AI glasses and its Muse agent. We also look at Anthropic's biology lab findings, a new method for breaking RSA encryption, and Enveda's latest funding for nature-derived AI drugs.
1 of 7 · OpenAI
OpenAI extends cyber access to Ukraine for civilian defense
OpenAI is extending access to its Daybreak program to the Government of Ukraine to support the cyber defense of civilian infrastructure.
Read the full story →2 of 7 · OpenAI
Two years of OpenAI Academy
OpenAI Academy marked its second anniversary and announced an expansion of its AI skills programs to additional communities.
Read the full story →3 of 7 · TechCrunch AI
Meta introduces camera-free AI glasses
Meta introduced a new version of its AI glasses that omits a camera, resulting in a lighter design and up to 12 hours of battery life.
Read the full story →4 of 7 · TechCrunch AI
Everything new coming to Meta’s AI agent Muse
Meta CEO Mark Zuckerberg announced expanded capabilities for the company's AI agent Muse during his keynote at the annual Connect event in Menlo Park. The updates include integration with Meta's AI glasses.
Read the full story →5 of 7 · TechCrunch AI
Anthropic says its biology lab has already found something big
Anthropic reported an early significant finding from its biology lab, where its Claude AI system is being used for research. The company said humans remain involved in overseeing the work rather than allowing the AI to operate autonomously.
Read the full story →6 of 7 · Ars Technica
There's a new way to break RSA that's faster than anything we've seen before
Researchers have identified a new method for breaking RSA encryption that operates faster than previously known approaches, which had relied on factoring. The discovery challenges the long-held assumption that factoring was the only viable path to compromising RSA.
Read the full story →7 of 7 · TechCrunch AI
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda raised $311 million at a $2 billion valuation to advance its nature-derived, AI-developed drugs into clinical trials. The biotech is currently testing treatments for skin conditions and for preserving weight loss after patients stop taking GLP-1 drugs.
Read the full story →That is today's roundup. Follow the links for the full stories, and we will see you tomorrow morning.
Morning Roost Issue #94